• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Salix says FDA won't approve Xifaxan for irritable bowel syndrome

Salix says FDA won't approve Xifaxan for irritable bowel syndrome

March 1, 2011
CenterWatch Staff

Salix Pharmaceuticals, a maker of drugs for gastrointestinal disorders, said U.S. regulators won’t approve its Xifaxan for a form of irritable bowel syndrome, Bloomberg News reported.

The FDA will issue what’s known as a complete response letter for the added use of Xifaxan, Salix said in a statement. Company-funded research published in the New England Journal of Medicine in January showed Xifaxan, already cleared for traveler’s diarrhea and a rare brain disorder caused by liver failure, helped ease irritable bowel symptoms such as abdominal pain and diarrhea.

“I wouldn’t ever call an FDA action a slam dunk, but certainly expectations were sky high,” said Corey Davis, an analyst with Jefferies & Co. in an e-mail. “There have been very few drugs I can think of that had a publication in NEJM and then subsequently never received FDA approval. Salix got sucker punched by the FDA.”

An FDA decision had been expected by March 7 for the new use of Xifaxan as a remedy for non-constipation irritable bowel syndrome, Salix said. Instead, Salix said regulators indicated the expanded use “is not ready for approval primarily due to a newly expressed need for retreatment.”

If Salix is required to conduct a new trial for repeat dosing of its drug, it would cost tens of millions and take years to complete, Davis said. The company said it would consider next steps once it receives the FDA’s letter.

At least 30 million people in the U.S. suffer from irritable bowel syndrome, and the most common symptom is diarrhea, said Mark Pimentel, lead author of the research reported from January. Most patients are treated with antidepressants, fiber supplements or diet and lifestyle changes, he said. Xifaxan, if approved to combat the syndrome, may help patients who don’t have constipation, he said.

The drug could be the first “that is treating a causative factor in irritable bowel syndrome,” said Pimentel, director of the GI Motility Program at Cedars-Sinai Medical Center in Los Angeles.

 

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing